Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Transcriptional profiles and stromal changes reveal bone marrow adaptation to early breast cancer in association with deregulated circulating microRNAs.

Chiodoni C, Cancila V, Renzi TA, Perrone M, Tomirotti AM, Sangaletti S, Botti L, Dugo M, Milani M, Bongiovanni L, Marrale M, Tripodo C, Colombo MP.

Cancer Res. 2019 Nov 27. pii: canres.1425.2019. doi: 10.1158/0008-5472.CAN-19-1425. [Epub ahead of print]

2.

Inhibition of DNA damage response at telomeres improves the detrimental phenotypes of Hutchinson-Gilford Progeria Syndrome.

Aguado J, Sola-Carvajal A, Cancila V, Revêchon G, Ong PF, Jones-Weinert CW, Wallén Arzt E, Lattanzi G, Dreesen O, Tripodo C, Rossiello F, Eriksson M, d'Adda di Fagagna F.

Nat Commun. 2019 Nov 18;10(1):4990. doi: 10.1038/s41467-019-13018-3.

3.

Frontline Science: Mast cells regulate neutrophil homeostasis by influencing macrophage clearance activity.

Jachetti E, D'Incà F, Danelli L, Magris R, Dal Secco C, Vit F, Cancila V, Tripodo C, Scapini P, Colombo MP, Pucillo C, Frossi B.

J Leukoc Biol. 2019 Apr;105(4):633-644. doi: 10.1002/JLB.4HI1018-390R. Epub 2019 Feb 28.

PMID:
30817046
4.

WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer.

Castagnoli L, Cancila V, Cordoba-Romero SL, Faraci S, Talarico G, Belmonte B, Iorio MV, Milani M, Volpari T, Chiodoni C, Hidalgo-Miranda A, Tagliabue E, Tripodo C, Sangaletti S, Di Nicola M, Pupa SM.

Oncogene. 2019 May;38(21):4047-4060. doi: 10.1038/s41388-019-0700-2. Epub 2019 Jan 31.

5.

Drp1 Controls Effective T Cell Immune-Surveillance by Regulating T Cell Migration, Proliferation, and cMyc-Dependent Metabolic Reprogramming.

Simula L, Pacella I, Colamatteo A, Procaccini C, Cancila V, Bordi M, Tregnago C, Corrado M, Pigazzi M, Barnaba V, Tripodo C, Matarese G, Piconese S, Campello S.

Cell Rep. 2018 Dec 11;25(11):3059-3073.e10. doi: 10.1016/j.celrep.2018.11.018.

6.

Circulating mir-320a promotes immunosuppressive macrophages M2 phenotype associated with lung cancer risk.

Fortunato O, Borzi C, Milione M, Centonze G, Conte D, Boeri M, Verri C, Moro M, Facchinetti F, Andriani F, Roz L, Caleca L, Huber V, Cova A, Camisaschi C, Castelli C, Cancila V, Tripodo C, Pastorino U, Sozzi G.

Int J Cancer. 2019 Jun 1;144(11):2746-2761. doi: 10.1002/ijc.31988. Epub 2019 Jan 6.

7.

Transcriptional analysis distinguishes breast implant-associated anaplastic large cell lymphoma from other peripheral T-cell lymphomas.

Di Napoli A, De Cecco L, Piccaluga PP, Navari M, Cancila V, Cippitelli C, Pepe G, Lopez G, Monardo F, Bianchi A, D'Amore ESG, Gianelli U, Facchetti F, Berti E, Bhagat G.

Mod Pathol. 2019 Feb;32(2):216-230. doi: 10.1038/s41379-018-0130-7. Epub 2018 Sep 11.

PMID:
30206415
8.

Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade.

Lo Russo G, Moro M, Sommariva M, Cancila V, Boeri M, Centonze G, Ferro S, Ganzinelli M, Gasparini P, Huber V, Milione M, Porcu L, Proto C, Pruneri G, Signorelli D, Sangaletti S, Sfondrini L, Storti C, Tassi E, Bardelli A, Marsoni S, Torri V, Tripodo C, Colombo MP, Anichini A, Rivoltini L, Balsari A, Sozzi G, Garassino MC.

Clin Cancer Res. 2019 Feb 1;25(3):989-999. doi: 10.1158/1078-0432.CCR-18-1390. Epub 2018 Sep 11.

PMID:
30206165
9.

Cross-Talk between Myeloid-Derived Suppressor Cells and Mast Cells Mediates Tumor-Specific Immunosuppression in Prostate Cancer.

Jachetti E, Cancila V, Rigoni A, Bongiovanni L, Cappetti B, Belmonte B, Enriquez C, Casalini P, Ostano P, Frossi B, Sangaletti S, Chiodoni C, Chiorino G, Pucillo CE, Tripodo C, Colombo MP.

Cancer Immunol Res. 2018 May;6(5):552-565. doi: 10.1158/2326-6066.CIR-17-0385. Epub 2018 Mar 9.

10.

Real-time detection of BRAF V600E mutation from archival hairy cell leukemia FFPE tissue by nanopore sequencing.

Vacca D, Cancila V, Gulino A, Lo Bosco G, Belmonte B, Di Napoli A, Florena AM, Tripodo C, Arancio W.

Mol Biol Rep. 2018 Feb;45(1):1-7. doi: 10.1007/s11033-017-4133-0. Epub 2017 Dec 13.

PMID:
29238890
11.

Trabectedin Overrides Osteosarcoma Differentiative Block and Reprograms the Tumor Immune Environment Enabling Effective Combination with Immune Checkpoint Inhibitors.

Ratti C, Botti L, Cancila V, Galvan S, Torselli I, Garofalo C, Manara MC, Bongiovanni L, Valenti CF, Burocchi A, Parenza M, Cappetti B, Sangaletti S, Tripodo C, Scotlandi K, Colombo MP, Chiodoni C.

Clin Cancer Res. 2017 Sep 1;23(17):5149-5161. doi: 10.1158/1078-0432.CCR-16-3186. Epub 2017 Jun 9.

12.

Imatinib Spares cKit-Expressing Prostate Neuroendocrine Tumors, whereas Kills Seminal Vesicle Epithelial-Stromal Tumors by Targeting PDGFR-β.

Jachetti E, Rigoni A, Bongiovanni L, Arioli I, Botti L, Parenza M, Cancila V, Chiodoni C, Festinese F, Bellone M, Tardanico R, Tripodo C, Colombo MP.

Mol Cancer Ther. 2017 Feb;16(2):365-375. doi: 10.1158/1535-7163.MCT-16-0466. Epub 2016 Dec 15.

13.

NUPR1, a new target in liver cancer: implication in controlling cell growth, migration, invasion and sorafenib resistance.

Emma MR, Iovanna JL, Bachvarov D, Puleio R, Loria GR, Augello G, Candido S, Libra M, Gulino A, Cancila V, McCubrey JA, Montalto G, Cervello M.

Cell Death Dis. 2016 Jun 23;7(6):e2269. doi: 10.1038/cddis.2016.175.

Supplemental Content

Loading ...
Support Center